menu

We’re all in this TOGETHER

Margenza® (margetuximab-cmkb) injection logo

Situation

With a pipeline of products using innovative monoclonal antibody-based platforms for the treatment of cancer, MacroGenics is a company on the rise. When it became apparent that the FDA was going to approve MARGENZA quicker than expected, MacroGenics needed a partner who would rise to the occasion as well. Enter EVERSANA ENGAGE to deliver websites, collateral, sales material, and more, helping patients with metastatic breast cancer have access to a late-stage option they previously lacked.

Solution

As only 20% of breast cancer patients are HER2+ and are more likely to be fighters than survivors, we created an impactful “adcept” that combined the benefits of MARGENZA (efficacy, safety, and flexibility) with the visual camaraderie of patients alongside HCPs. Literally, TO GET HER a chance for more time becomes TOGETHER. This concept served as the basis for the HCP and patient campaigns, and makes a bold statement from MacroGenics that they may be new, but they are here to make an impact on patients’ lives.

Impact

MARGENZA was launched in March 2021, and the following were created, MLR-approved, and completed within the year:

  • Now Approved website
  • Now Available website
  • Full Campaign website
  • MARGENZA Access Support website
  • Copay and Patient Assistance Program forms
  • Billing and Coding Guide
  • FAQ/objection handlers for representatives
  • MARGENZA Fact Sheet
  • MOA video and leave-behind
  • MARGENZA Patient Brochure
  • Banner ad campaign generating 21 million impressions
  • Print advertisements in leading journals
  • Convention sponsorship

The result

An energized sales force, an interested HCP audience, and patients who are benefiting from having the option of MARGENZA.

Like the thinking? Take the NEXT step with us.

Contact Us